Pharmacodynamic (PD), pharmacokinetic (PK) and safety profile of formoterol delivered via two different dry powder inhalers (DPIs)

H. Dietrich, T. D. Nguyen, U. Buermann, U. Petzold, U. Munzel, J. Maus (Cologne, Bad Homburg, Germany)

Source: Annual Congress 2006 - Respiratory diseases in primary care
Session: Respiratory diseases in primary care
Session type: Electronic Poster Discussion
Number: 3606
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Dietrich, T. D. Nguyen, U. Buermann, U. Petzold, U. Munzel, J. Maus (Cologne, Bad Homburg, Germany). Pharmacodynamic (PD), pharmacokinetic (PK) and safety profile of formoterol delivered via two different dry powder inhalers (DPIs). Eur Respir J 2006; 28: Suppl. 50, 3606

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012

Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

Variability of budesonide (BUD) fine particle dose (FPD) delivered through two multiple dose dry powder inhalers (MDPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs)
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Systemic bioavailability (BA) and pharmacodynamics (PD) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) or a novel breath-triggered inhaler (BTI)
Source: International Congress 2017 – Inhalers and their use
Year: 2017


Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI)
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003

Comparison of a formoterol multiple dose dry powder inhaler (MDPI) with a formoterol single dose dry powder inhaler (SDPI) in patients with moderate to severe asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 260s
Year: 2004

Population pharmacokinetic (PK) analysis of fluticasone furoate (FF)/umeclidimium (UMEC)/vilanterol (VI) via a single inhaler in patients with COPD (FULFIL)
Source: International Congress 2017 – Management of COPD
Year: 2017


In-vitro product performance of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) delivered from a dry powder inhaler (DPI) using the Electronic Lung (EL) to replicate patient inhalation profiles
Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies
Year: 2019


Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI)
Source: Eur Respir J 2003; 22: Suppl. 45, 472s
Year: 2003

The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjects
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Dosage form proportionality, dose proportionality and pharmacokinetics (PK) of mometasone furoate (MF) and formoterol fumarate (F) from three combination MDI formulations
Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008

Bronchodilator effect of formoterol delivered by two different dry powder inhalers (DPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 310s
Year: 2004

Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI)
Source: Eur Respir J 2005; 26: Suppl. 49, 126s
Year: 2005

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005